The company has R&D operations and management teams in Guangzhou, China and San Francisco, USA. It has 500 square meters of experimental and office space, with 10,000-class cell rooms and SPF-class animal rooms, which can carry out in vivo and in vitro experiments. The company also makes full use of high-quality CRO companies for pre-clinical testing and GMP drug production.
CGX1321 is a novel WNT pathway inhibitor. Through inhibition of Porcupine in WNT secreting cells, CGX1321 has specific anti-cancer effects on tumors with RSPO gene fusion and RNF43 gene mutation.
Curegenix is a clinical-stage company with operations in the San Francisco Bay Area and Guangzhou China. We focus on the discovery and development of novel drugs.